Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 35^th Annual Life Sciences Conference on Tuesday, February 11, 2025 at 4:40 p.m. ET.